Friday 21 December, 2007

PhytoMedical Expands Scope of Patented Technology That Kills Cancer Cells

PhytoMedical Technologies (in a press release) announced that it has expanded the research and development of a novel class of anti-cancer agents which have a ‘cytotoxic’ or poisonous affinity for cancer cells.
These patented anti-cancer compounds are designed to bind more tightly to cancer cell DNA than many conventional anti-cancer drugs by a process called bis-intercalation or “double binding,” much like a molecular staple. Because the DNA is the blueprint of life for the cancer cell, such binding stops the replication of the DNA, which prevents the growth of the cancer cell and it dies.
“Initial studies using a leukemia cell line demonstrated that such double binding or intercalation stopped the replication of the DNA, and, ultimately, lead to the death of the cancer cells,” states Mr. Greg Wujek, President, CEO of PhytoMedical Technologies, Inc. “The positive initial results and the strength of intellectual property surrounding the technology has given us the confidence to expand our research in order to improve upon the concept of bis-intercalation and the promise it holds for the control of cancer.”
In response to the success of the studies, PhytoMedical’s collaborating scientists are now synthesizing and testing new derivatives of these anti-cancer agents. Further tests of the “DNA binding” anti-cancer agents are planned for human cancer cell lines specific to glioblastoma (tumors related to the brain) and small cell lung cancer, both of which are associated with a high mortality rate.
Mr. Greg Wujek concludes, “Our goal is to identify the compound that demonstrate the greatest anti-cancer activity and successfully complete the preclinical steps required for an Investigational New Drug Application.”

No comments:

web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker